Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/JPRN-UMIN000013343
JPRN-UMIN000013343CompletedPhase 4

Assessment of suitable Antihypertensive therapies: Combination with high dose amlodipine/Irbesartan vs. triple combination with amlodipine/Irbesartan/Indapamide - ASAHI-AI study

Asahikawa Medical University0 sites94 target enrollmentStarted: March 6, 2014Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 4
Status
Completed
Enrollment
94
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

High-dose CCBs combined with ARBs and a triple combination with diuretics combined with standard-dose CCB/ARBs produced a similar efficacy in reducing the BP. Both combination therapies can be used safely and effectively in hypertensive patients uncontrolled by standard doses of ARBs and CCBs.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
20years-old to 85years-old (—)
Sex
All

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •1) Patients with secondary hypertension 2) Patients with a history of severe renal disease: serum creatinine>2.0 mg/dl 3) Patients with critical liver damage (AST or ALT>100 IU/l) 4) Patients with a history of adverse effects to ARBs 5) Bilateral renal artery stenosis 6) Patients with hyperkalemia >=5.5 mEq/L 7) Patients with pregnancy or breast-feeding 8) Patients with a poor prognosis such as a malignant tumor 9) Patients who are considered not to be eligible for the study by the investigator due to medical reasons

Investigators

Similar Trials

Unknown
Not Applicable
ARB and CCB Longest Combination Treatment on Ambulatory and Home BP in Hypertension With Atrial Fibrillation -Multicenter Study on Time of Dosing (ACROBAT)Hypertension and Atrial Fibrillation
NCT01748253Acrobat Trial Group80
Completed
Phase 4
Kanagawa Combination Anti-hypertensive Therapy (K-CAT)Hypertension
NCT00492128Yokohama City University Medical Center196
Unknown
Phase 4
Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive PatientsEssential Hypertension
NCT01011660Chinese Academy of Medical Sciences, Fuwai Hospital13,542
Unknown
Not Applicable
Community-based Microalbuminuria Screening in Patients With HypertensionMicroalbuminuriaHypertension
NCT03596840Shanghai Zhongshan Hospital3,000
Completed
Not Applicable
Evaluation for drug combination of antihypertensive agent and lipid-lowering agent in patients with hypertension and dyslipidemiaHypertension and dyslipidemia
JPRN-UMIN000008539Saitama Medical Center, Saitama Medical University30